Have you seen the new evidence supporting antibody-drug conjugates (ADCs) for the treatment of triple-negative breast cancer (TNBC)? Can you recognize treatment directions based on biomarkers, such as HER2-low and HER2 overexpression?
This educational series examines the rapidly evolving landscape of breast cancer treatment. Tune in to hear our globally renowned experts break down current and emerging ADCs that could benefit your patients with TNBC and HER2 breast cancer.
Provided by:
In Partnership with:
Clinical Implications of Current Guidelines on First-Line Immunotherapy and PARP Inhibitors for TNBC
Peter Schmid, FRCP, MD, PhD
PeerErica L. Mayer, MD, MPH
PeerErica L. Mayer, MD, MPH
PeerErica L. Mayer, MD, MPH
PeerThe Role of HER2-Directed Therapy for Second-Line Treatment of HER2+ Metastatic Breast Cancer
Peter Schmid, FRCP, MD, PhD
PeerPeter Schmid, FRCP, MD, PhD
PeerWilliam J. Gradishar, MD
PeerPeter Schmid, FRCP, MD, PhD
PeerWilliam J. Gradishar, MD
Peer